Article
Cardiac & Cardiovascular Systems
Ae-Young Her, Eun-Seok Shin, Sunwon Kim, Bitna Kim, Tae-Hyun Kim, Chang-Bae Sohn, Byung Joo Choi, Yongwhi Park, Jung Rae Cho, Young-Hoon Jeong
Summary: This study investigated the clinical impact of drug-coated balloon (DCB) treatment in patients with diabetes mellitus (DM) and multivessel coronary artery disease (CAD), and found that DCB treatment reduced the risk of major adverse cardiovascular events (MACE) in patients with DM, but not in those without DM.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Dong-Woo Choi, Choongki Kim, Yongsung Suh, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Eun-Cheol Park, Yangsoo Jang, Chung-Mo Nam, Myeong-Ki Hong
Summary: This study suggests that prolonged DAPT may be beneficial for diabetic patients who have undergone drug-eluting stent implantation. The findings indicate that extending the duration of dual antiplatelet therapy in these patients may reduce the risk of all-cause death.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Pawel Gasior, Marek Gierlotka, Krzysztof Szczurek-Katanski, Marcin Osuch, Magda Roleder, Michal Hawranek, Wojciech Wojakowski, Lech Polonski
Summary: The study compared the 1-year clinical outcomes of thin-strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) and durable coating everolimus-eluting stent (DP-EES) in diabetic patients, finding no significant differences in efficacy and safety outcomes between the two types of stents.
CARDIOLOGY JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Masato Nakamura, Kazushige Kadota, Yoshihisa Nakagawa, Kengo Tanabe, Yoshiaki Ito, Tetsuya Amano, Yuichiro Maekawa, Akihiko Takahashi, Nobuo Shiode, Yoritaka Otsuka, Tomohiro Kawasaki, Yutaka Hikichi, Junya Shite, Ken Kozuma, Raisuke Iijima, Yoshitaka Murakami
Summary: This randomized comparison study showed that ultrathin-strut drug-eluting stents were noninferior to thin-strut drug-eluting stents in terms of target lesion failure at 1 year, indicating that differences in strut thickness among DES have little impact on clinical outcomes when implanted with intravascular imaging guidance.
JACC-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Medicine, General & Internal
Minsu Kim, Albert Youngwoo Jang, Joonpyo Lee, Jeongduk Seo, Yong Hoon Shin, Pyung Chun Oh, Soon Yong Suh, Kyounghoon Lee, Woong Chol Kang, Seung-Hwan Han
Summary: This study compared the clinical outcomes of drug-eluting balloon (DEB) angioplasty and drug-eluting stent (DES) implantation in DES in-stent restenosis (ISR) lesions. The results showed that there was no significant difference in target lesion revascularization between the DEB and DES groups during the 7-year follow-up period. However, the DEB group had better safety outcomes, with lower rates of myocardial infarction and target lesion thrombosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Yong Hoon Kim, Ae-Young Her, Myung Ho Jeong, Byeong-Keuk Kim, Sung-Jin Hong, Seunghwan Kim, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Summary: The study found that second-generation drug-eluting stents were more effective in reducing 2-year clinical outcomes for patients with prediabetes and diabetes compared to first-generation stents.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Tobias Lenz, Tobias Koch, Michael Joner, Erion Xhepa, Jens Wiebe, J. J. Coughlan, Alp Aytekin, Tareq Ibrahim, Massimiliano Fusaro, Salvatore Cassese, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati, Sebastian Kufner
Summary: This study compared the 10-year clinical outcomes of patients with and without diabetes mellitus after treatment with new-generation drug-eluting stents. The results showed that patients with diabetes mellitus had significantly higher rates of major adverse cardiac events compared to those without diabetes mellitus.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Rafael Romaguera, Pablo Salinas, Josep Gomez-Lara, Salvatore Brugaletta, Antonio Gomez-Menchero, Miguel A. Romero, Sergio Garcia-Blas, Raymundo Ocaranza, Pascual Bordes, Marcelo Jimenez Kockar, Neus Salvatella, Victor A. Jimenez-Diaz, Mar Alameda, Ramiro Trillo, Dae Hyun Lee, Pedro Martin, Maria Lopez-Benito, Alfonso Freites, Virginia Pascual-Tejerina, Felipe Hernandez-Hernandez, Bruno Garcia Del Blanco, Mohsen Mohandes, Francisco Bosa, Eduardo Pinar, Gerard Roura, Josep Comin-Colet, Antonio Fernandez-Ortiz, Carlos Macaya, Xavier Rossello, Manel Sabate, Stuart J. Pocock, Joan A. Gomez-Hospital
Summary: In a randomized controlled trial in Spain, researchers compared the Cre8 EVO stent with the Resolute Onyx stent in patients with diabetes undergoing percutaneous coronary intervention. The study found that the Cre8 EVO stent was non-inferior to the Resolute Onyx stent in terms of target-lesion failure composite outcome, with a suggestion of potential superiority for the Cre8 EVO stent at 1 year follow-up.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Fumi Yamamoto, Masahiro Natsuaki, Shoichi Kuramitsu, Masanobu Ohya, Hiromasa Otake, Kazunori Horie, Futoshi Yamanaka, Hiroki Shiomi, Gaku Nakazawa, Kenji Ando, Kazushige Kadota, Shigeru Saito, Takeshi Kimura, Koichi Node
Summary: This study assessed the association between clinical presentation at index procedure and mortality in patients with second-generation drug-eluting stent thrombosis. The results showed that the cumulative 3-year incidence of all-cause death after the index ST events was similar between patients with acute coronary syndrome (ACS) and chronic coronary syndrome (CCS), but patients in the ACS group were more likely to have early ST and higher incidences of target lesion revascularization and recurrent ST compared to the CCS group.
JACC-CARDIOVASCULAR INTERVENTIONS
(2021)
Article
Medicine, Research & Experimental
Yi-Xing Yang, Huai-Peng Zhang, Chuang Li, Yuan Fu, Kui-Zheng He, Xin-Ming Liu, Hong-Jiang Wang, Kun Xia, Li Xu, Jiu-Chang Zhong, Mu-Lei Chen, Le-Feng Wang
Summary: This study investigated the safety and efficiency of drug eluting balloon (DEB) versus drug eluting stent (DES) in cancer patients with acute myocardial infarction (AMI). The results showed that DEB had a trend towards lower rate of major adverse cardiovascular events (MACE) compared with DES in this high-risk group.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Review
Public, Environmental & Occupational Health
Kui Li, Kaijun Cui, Xuechuan Dan, Jian Feng, Xiaobo Pu
Summary: This meta-analysis suggests that drug-coated balloon (DCB) has better short-term therapeutic efficacy and safety than drug-eluting stent (DES) for treating small-vessel coronary artery lesions in diabetic patients.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Cardiac & Cardiovascular Systems
Hong Wang, Quannan Zu, Hairong Tang, Ming Lu, Rongfa Chen, Zhiren Yang
Summary: Diabetes mellitus is a major risk factor for cardiovascular diseases, and the use of biodegradable polymer drug-eluting stents (BP-DES) can reduce the risk of restenosis. However, diabetic patients implanted with BP-DES have a significantly higher risk of adverse cardiovascular events.
CARDIOVASCULAR DIABETOLOGY
(2023)
Review
Medicine, General & Internal
Baoyu Geng, Zhe Liu, Guangzhi Feng, Jun Jiang
Summary: This study is a high-quality systematic review and meta-analysis comparing the efficacy and safety of DCB and DES in patients with acute myocardial infarction. The results suggest that the use of DCB may be associated with a reduced risk of cardiovascular disease and death.
Article
Cardiac & Cardiovascular Systems
Yi-Xing Yang, Kui-Zheng He, Jiang-Yuan Li, Yuan Fu, Chuang Li, Xin-Ming Liu, Hong-Jiang Wang, Mu-Lei Chen, Pi-Xiong Su, Li Xu, Le-Feng Wang
Summary: The present study investigated the safety and effectiveness of drug-eluting balloons (DEBs) in young patients with acute myocardial infarction (AMI). The results showed that patients treated with DEBs had a trend toward a lower incidence of device-oriented composite endpoint (DOCE) compared to those treated with drug-eluting stents (DESs). This suggests that DEBs might be a potential treatment option in young patients with AMI.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
(2023)
Article
Cardiac & Cardiovascular Systems
Jochen Woehrle, Bruno Scheller, Julia Seeger, Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Moebius-Winkler, Daniel Weilenmann, Georg Stachel, Gregor Leibundgut, Peter Rickenbacher, Marco Cattaneo, Nicole Gilgen, Christoph Kaiser, Raban Jeger
Summary: This study evaluated the impact of diabetes on clinical outcomes in patients receiving DCB or DES treatment for de novo lesions. The study found that rates of major adverse cardiac events were similar between DCB and DES in both diabetic and nondiabetic patients, but diabetic patients had significantly lower rates of target vessel revascularization with DCB compared to DES.
JACC-CARDIOVASCULAR INTERVENTIONS
(2021)